Newer Breast MRI Sequences for the Evaluation of Breast Cancer - Vibrant-DE and IDEAL: Feasibility Evaluation - Full Text View

Newer Breast MRI Sequences for the Evaluation of Breast Cancer - Vibrant-DE and IDEAL: Feasibility Evaluation

This study is currently recruiting participants.
Verified by Memorial Sloan-Kettering Cancer Center, October 2008

Sponsored by:	Memorial Sloan-Kettering Cancer Center
Information provided by:	Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:	NCT00579800

Purpose

The purpose of this study is to evaluate new computer software on breast magnetic resonance imaging (MRI). The information from this study may help doctors and scientists develop better ways to find breast cancer, and may help future patents with cancer.

Condition	Intervention
Breast Cancer	Other: new software sequences, Vibrant-DE and IDEAL

Genetics Home Reference related topics:

breast cancer

MedlinePlus related topics:

Breast Cancer Cancer

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Open Label, Single Group Assignment, Efficacy Study

Official Title:	Newer Breast MRI Sequences for the Evaluation of Breast Cancer - Vibrant-DE and IDEAL: Feasibility Evaluation

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:

To quantitatively and qualitatively assess performance of the two breast pulse sequences, and compare these results with the same parameters on standard breast MRI sequences. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	20
Study Start Date:	July 2007
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Intervention Details:

new software sequences, Vibrant-DE and IDEAL, for breast magnetic resonance imaging (MRI)

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Female patients over the age of 21 undergoing a diagnostic Breast MRI.

Exclusion Criteria:

Patients who would be normally excluded from undergoing an MRI examination
Patients with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field.
Patients under the age of 21.
Female patients who are pregnant.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00579800

Contacts


Contact: Elizabeth Morris, MD		morrise@mskcc.org

Locations


United States, New York
	Memorial Sloan-Kettering Cancer Center	Recruiting
	New York, New York, United States, 10065
	Contact: Elizabeth Morris, MD morrise@mskcc.org

Sponsors and Collaborators

Memorial Sloan-Kettering Cancer Center

Investigators


Principal Investigator:	Elizabeth Morris, MD	Memorial Sloan-Kettering Cancer Center

More Information

Memorial Sloan-Kettering Web Site This link exits the ClinicalTrials.gov site

Responsible Party:	Memorial Sloan-Kettering Cancer Center ( Elizabeth Morris, MD )
Study ID Numbers:	07-091
First Received:	December 20, 2007
Last Updated:	October 1, 2008
ClinicalTrials.gov Identifier:	NCT00579800
Health Authority:	United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:

Vibrant-DE

IDEAL

MRI

Breast

Study placed in the following topic categories:

Skin Diseases

Breast Neoplasms

Breast Diseases

Additional relevant MeSH terms:

Neoplasms

Neoplasms by Site

ClinicalTrials.gov processed this record on October 10, 2008